Ástralía - enska - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 25 microgram/ml - injection, solution - excipient ingredients: ethanol; propylene glycol; citric acid; dibasic sodium phosphate; water for injections - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Bandaríkin - enska - NLM (National Library of Medicine)

jerome stevens pharmaceuticals, inc. - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 125 ug - heart failure: digoxin is indicated for the treatment of mild to moderate heart failure. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by exercise capacity and heart failure symptoms as evidenced by exercise capacity and heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. atrial fibrillation: digoxin is indicated for the control of ventricular response rate in patients with chronic atrial fibrillation. digitalis glycosides are contraindicated in patients with ventricular fibrillation or in patients with a known hypersensitivity to digoxin. a hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to digoxin.

Bandaríkin - enska - NLM (National Library of Medicine)

precision dose inc. - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.05 mg in 1 ml - digoxin oral solution, usp is indicated for the treatment of mild to moderate heart failure. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by increased exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. digoxin increases myocardial contractility in pediatric patients with heart failure. digoxin oral solution, usp is indicated for the control of resting ventricular response rate in patients with chronic atrial fibrillation. digoxin should not be used for the treatment of multifocal atrial tachycardia. allergy to digoxin is rare. digoxin is contraindicated in patients with a known hypersensitivity to digoxin or other forms of digitalis. digitalis glycosides, such as digoxin, are contraindicated in ventricula

Bandaríkin - enska - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 125 ug - heart failure: digoxin is indicated for the treatment of mild to moderate heart failure. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by exercise capacity and heart failure symptoms as evidenced by exercise capacity and heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. atrial fibrillation: digoxin is indicated for the control of ventricular response rate in patients with chronic atrial fibrillation. digitalis glycosides are contraindicated in patients with ventricular fibrillation or in patients with a known hypersensitivity to digoxin. a hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to digoxin.

Bandaríkin - enska - NLM (National Library of Medicine)

covis pharma us, inc - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 250 ug in 1 ml - lanoxin is indicated for the treatment of mild to moderate heart failure in adults. lanoxin increases left ventricular ejection fraction and improves heart failure symptoms, as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, lanoxin should be used in combination with a diuretic and an angiotensin-converting enzyme (ace) inhibitor. lanoxin increases myocardial contractility in pediatric patients with heart failure. lanoxin is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation. lanoxin is contraindicated in patients with: experience with digoxin in pregnant women over several decades, based on published retrospective clinical studies and case reports, has not led to the identification of a drug associated risk of major birth defects, miscarriage or adverse maternal and fetal outcomes. untreated underlying maternal conditions, such as heart

Bandaríkin - enska - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.05 mg in 1 ml - digoxin oral solution is indicated for the treatment of mild to moderate heart failure. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by increased exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. digoxin is indicated to increase myocardial contractility in pediatric patients with heart failure. digoxin oral solution is indicated for the control of resting ventricular response rate in patients with chronic atrial fibrillation. digoxin should not be used for the treatment of multifocal atrial tachycardia. allergy to digoxin is rare. digoxin is contraindicated in patients with a known hypersensitivity to digoxin or other forms of digitalis. digitalis glycosides, such as digoxin, are contraindicated in ventricular fibrillation. teratogenic effects animal reproduction studies have not been conducted with digoxin. it is also not known whether digoxin can cause fetal harm when administered to pregnant women or can affect reproductive capacity. digoxin should be given to a pregnant woman only if clearly needed. there is not enough data from clinical trials to determine the safety and efficacy of digoxin during labor and delivery. digoxin levels in human milk are lower than those in maternal serum. the estimated exposure that a nursing infant would be expected to receive via breastfeeding would be far below the usual infant maintenance dose. therefore, this amount should have no pharmacologic effect upon the infant. nevertheless, caution should be exercised when digoxin is administered to a nursing woman. digoxin increases myocardial contractility in pediatric patients with congestive heart failure. there are no clinical efficacy studies demonstrating benefit in pediatric patients with heart failure. there are no controlled randomized studies of digoxin in pediatric patients with atrial tachyarrhythmias [see clinical studies (14.2)] . the majority of clinical experience gained with digoxin has been in the elderly population. this experience has not identified differences in response or adverse effects between the elderly and younger patients. however, this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, which should be based on renal function, and it may be useful to monitor renal function [see dosage and administration (2.4)] . no clinically significant gender differences in digoxin pharmacokinetics have been reported. the clearance of digoxin can be primarily correlated with renal function as indicated by creatinine clearance. table 3 provides the usual daily maintenance dose requirements of solution based on creatinine clearance (per 70 kg or per 1.73 m2 ) [see dosage and administration (2.4) ]. for pediatric patients with known or suspected renal dysfunction, lower starting doses should be considered combined with frequent monitoring of digoxin levels. plasma digoxin concentrations in patients with acute hepatitis generally fall within the range of profiles in a group of healthy subjects. in hyperthyroidism, lower serum digoxin concentrations have been reported because of decreased absorption. hypothyroid patients may require smaller doses of digoxin. race differences in digoxin pharmacokinetics have not been formally studied, but are not expected. the absorption of digoxin is reduced in some malabsorption conditions such as chronic diarrhea. instructions for use digoxin oral solution, usp oral syringe important information about measuring digoxin oral solution 1. insert the tip of the oral syringe into the medicine bottle. 2. pull back the plunger to the line that matches the dose prescribed by your healthcare provider. 3. remove the oral syringe from the medicine bottle. 4. take your medicine by slowly pushing the plunger until the oral syringe is empty. figure 1 distributed by: hikma pharmaceuticals usa inc. berkeley heights, nj 07922 c50000480/01 revised august 2023

Bandaríkin - enska - NLM (National Library of Medicine)

covis pharmaceuticals inc - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 100 ug in 1 ml - lanoxin is indicated for the treatment of mild to moderate heart failure. lanoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by exercise capacity and heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, lanoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these 3 drugs cannot be specified. lanoxin is indicated for the control of ventricular response rate in patients with chronic atrial fibrillation. digitalis glycosides are contraindicated in patients with ventricular fibrillation or in patients with a known hypersensitivity to digoxin. a hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to digoxin.

Bandaríkin - enska - NLM (National Library of Medicine)

clinical solutions wholesale, llc - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 125 ug - digoxin tablets, usp are indicated for the treatment of mild to moderate heart failure in adults. digoxin tablets, usp increase left ventricular ejection fraction and improve heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin tablets, usp should be used in combination with a diuretic and an angiotensin-converting enzyme (ace) inhibitor. digoxin tablets, usp increase myocardial contractility in pediatric patients with heart failure. digoxin tablets, usp are indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation. digoxin tablets are contraindicated in patients with: - ventricular fibrillation [see warnings and precautions (5.1)] - known hypersensitivity to digoxin (reactions seen include unexplained rash, swelli

Bandaríkin - enska - NLM (National Library of Medicine)

state of florida doh central pharmacy - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.125 mg - digoxin is indicated for the treatment of mild to moderate heart failure in adults. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used in combination with a diuretic and an angiotensin-converting enzyme (ace) inhibitor. digoxin increases myocardial contractility in pediatric patients with heart failure. digoxin is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation. digoxin is contraindicated in patients with: digoxin should be given to a pregnant woman only if clearly needed. it is also not known whether digoxin can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. animal reproduction studies have not been conducted with digoxin. there are not enough data from clinical trials to determin

Kanada - enska - Health Canada

sandoz canada incorporated - digoxin - liquid - 0.05mg - digoxin 0.05mg - cardiotonic agents